All In Biotech

Drug Trial Radar · NCT03439280

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Feb 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

50

Actual

Start

Apr 20, 2018

Primary completion

Jan 28, 2022

Study completion Jan 28, 2022

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Feb 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone (PomDex) in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-079 monotherapy in Phase 2a in participants with r/r MM.

Conditions

  • Relapsed/Refractory
  • Multiple Myeloma

Interventions

  • MezagitamabDrug

    Mezagitamab subcutaneously.

  • PomalidomideDrug

    Pomalidomide orally.

  • DexamethasoneDrug

    Dexamethasone orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)Time frame: From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  2. Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (cycle length=28 days)
  3. Phase 1: Number of Participants With Grade 3 or Higher TEAEsTime frame: From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  4. Phase 1: Number of Participants With Serious TEAEsTime frame: From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  5. Phase 1: Number of Participants With TEAEs Leading to Treatment DiscontinuationTime frame: From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  6. Phase 1: Number of Participants With TEAEs Leading to Dose ModificationsTime frame: From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  7. Phase 2a: Overall Response Rate (ORR)Time frame: Up to approximately 3.7 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope - Duarte

    Duarte, California

  • Washington University School of Medicine

    St Louis, Missouri

  • Mount Sinai Hospital-The Donald H. Ruttenberg Cancer Treatment Center

    New York, New York

  • Weill Cornell Medical Center, Div. of Hematology Medical Oncology

    New York, New York

  • Oregon Health & Science University Knight Cancer Institute

    Portland, Oregon

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.